NCT02407041已完成2 期
A Single-Center, Open-Label Phase 2a Clinical Trial to Evaluate the Safety and Efficacy of GR-MD-02 for the Treatment of Patients With Moderate to Severe Plaque Psoriasis
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 5
- 试验地点
- 1
- 主要终点
- Number of Participants With PASI-75, or a 75% Improvement From Baseline in PASI Score
研究概览
简要总结
Study GT-030 is a phase 2a, single-center, open-label study of subjects with moderate to severe plaque psoriasis
详细描述
The overall objective is to establish the safety and efficacy of GR-MD-02 in patients with moderate to severe plaque psoriasis.
Primary objective:
The objective is to evaluate the number of patients with moderate to severe plaque psoriasis who have 75% improvement in Psoriasis Activity Severity Index (PASI-75) following 12 weeks of therapy with GR-MD-02
Secondary objectives:
- To determine the PASI-50 and PASI-100 scores in patients with moderate to severe plaque psoriasis following the first 12 weeks of therapy with GR-MD-02
- To determine the PASI-50, PASI-75, and PASI-100 scores in patients with moderate to severe plaque psoriasis following an additional 12 weeks of therapy (total 24 weeks) with GR-MD-02
- To determine the durability of response to therapy in responders over a one year period following the end of therapy
- To determine whether there is any change in disease status of patients who also have psoriatic arthritis
- To determine the incidence of adverse events and vital sign and laboratory abnormalities during study treatment
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Each subject must meet all of the following criteria to be enrolled in this study:
- •Is capable of understanding the written informed consent, provides signed and witnessed written informed consent, and agrees to comply with protocol requirements.
- •Is between the ages of 18 and 75 years.
- •Has biopsy proven psoriasis and active moderate to severe plaque psoriasis with a PASI of ≥ 12 and at least 10% of involved body surface area.
- •The patient is not pregnant and must have a negative pregnancy test prior to start of the study. Post-menopausal women must have been amenorrheic for at least 12 months to be considered of non-child-bearing potential.
- •Sexually active men or women of childbearing potential must agree to use effective means of contraception throughout their participation in this study and for 90 days after discontinuation of study medication.
- •Lactating females must agree to discontinue nursing before the start of study treatment and refrain from nursing until 90 days after discontinuation of study medication.
- •Male subjects must refrain from sperm donation throughout the study period and for a period of 90 days following the last dose of study drug.
排除标准
- •Subjects meeting any of the following criteria will be excluded from the study:
- •Any medical illness that is not stable on therapy
- •Use of any biologic medication for psoriasis within 6 months
- •Use of or non-biological systemic therapy to include: methotrexate, oral retinoids, phototherapy/PUVA, cyclosporine, or any other cytotoxic or immunosuppressive medication within 4 weeks of start of study
- •Topical treatment that is likely to impact signs and symptoms of psoriasis, in the opinion of the Principal Investigator, within 2 weeks of the start of the study
- •Prior exposure to GR-MD-02
- •Known positivity for Human Immunodeficiency Virus (HIV) infection
- •Any patient who had major surgery within 8 weeks of Day 1, significant traumatic injury, or anticipation of need for major surgical procedure during the study.
- •Has a history of alcohol/drug abuse.
- •Any patient who has clinically significant and uncontrolled cardiovascular disease (e.g., uncontrolled hypertension, myocardial infarction, unstable angina), New York Heart Association (NYHA) Grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication, or Grade II or greater peripheral vascular disease within 12 months prior to Day
- •Any patient with concurrent infection including diagnoses of fever of unknown origin (FUO) (subjects must be afebrile at the start of therapy).
- •History of malignant disease with a recurrence of that disease within 5 years of follow-up except for those that have been curatively treated including basal or squamous cell carcinoma of the skin and in situ carcinoma of the cervix
- •Participation in an investigational new drug (IND) trial in the 30 days before randomization.
- •Clinically significant medical or psychiatric condition considered a high risk for participation in an investigational study.
- •Has donated or lost a significant volume (>450 mL) of blood or plasma within 30 days of the study.
- •Failure to give informed consent
- •Subjects with known allergies to the study drug or any of its excipients.
- •Is an employee or family member of the investigator or study site personnel.
研究组 & 干预措施
GR-MD-02
Experimental
active arm
干预措施: GR-MD-02 (Drug)
结局指标
主要结局
Number of Participants With PASI-75, or a 75% Improvement From Baseline in PASI Score
时间窗: 6 months
The primary endpoint will be the number of participants with PASI-75, or a 75% improvement from baseline (day 1, prior to first infusion) in PASI score as assessed at the 30 day follow up visit.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple MyelomaMultiple Myeloma in RelapseNCT03136653Molecular Partners AG33
终止
2 期
Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast CancerTriple Negative Breast CancerNCT05113966G1 Therapeutics, Inc.30
招募中
2 期
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial CancerEndometrial CancerNCT06463028Faeth Therapeutics40
进行中（未招募）
1 期
A multicentre, open label, phase IIb clinical trial to evaluate safety, tolerability and efficacy of the depigmented modified allergen extract of two mites mixes at 200 DPP/ml (DP/MG/14-1 Dermatophagoides pteronyssinus / Lepidoglyphus destructor and DP/MG/14-2 Dermatophagoides pteronyssinus /Blomia tropicalis) in subjects with allergic rhinitis or rhinoconjunctivitis, with controlled allergic asthma.EUCTR2014-000172-26-ESaboratorios LETI S.L.67
终止
2 期
Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene FusionsNSCLC, Stage IVNSCLC Stage IIIBNSCLC, Stage IIICNSCLC, RecurrentEGFR Exon 20 Insertion MutationHER2-activating MutationERBB FusionNRG1 FusionNCT03805841Rain Oncology Inc41